What to Expect From COVID This Fall
Speaking to media in a virtual briefing, infectious disease specialist Dr. Cameron Wolfe and David Montefiori, Ph.D., director of the Duke Human Vaccine Institute, said booster shots continue to be effective for those Americans who routinely get them.
Duke Launches Site for COVID Vaccine Study Among Health Care Workers
The Duke Clinical and Translational Science Institute (CTSI) is collaborating with the Duke Department of Emergency Medicine on a study to evaluate the effectiveness of COVID-19 vaccines and the long-term impact of infection among health care personnel.
Nearly 1 Million Tests Mark End to Part of Duke’s COVID-19 Response
Surveillance testing, as well as other aspects of COVID-19 response, come to an end on Duke's campus.
Analysis Details Lasting Effects of the Covid-19 Pandemic on Cancer Care
Cancer patients said the COVID-19 pandemic heightened infection concerns, increased feelings of fear, and disrupted their care, according to a research questionnaire.
Duke Human Vaccine Institute Wins Contract to Produce Pan-Coronavirus Vaccine
Production will enable human studies to determine whether the vaccine protects against a wide variety of coronaviruses, including those that cause COVID-19
Thomas Denny: Overseeing Duke’s Vaccine Research Enterprise
As chief operating officer at the Duke Human Vaccine Institute (DHVI), Thomas Denny is in the unique position of helping people fight flu and HIV, developing the next generation of COVID-19 vaccines, and all the while leading an annual $120 million enterprise.
Study Confirms No Benefit to Taking Ivermectin for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.
Study Finds No Benefit to Taking Fluvoxamine for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine 50 mg twice daily for 10 days for the treatment of mild-to-moderate COVID-19 symptoms.
Engaging the Community: Dr. Susanna Naggie
Dr. Susanna Naggie and her colleagues at Duke University School of Medicine knew that COVID-19 was disproportionately impacting communities of color through higher rates of infection, severity of disease and associated adverse outcomes. Determined to be part of the solution, they set out to understand and address these disparities in real time.
Communicating Truth: Dr. Cameron Wolfe
Dr. Wolfe emerged as a key figure at Duke during the pandemic, patiently explaining the threat to the public while helping shape both the hospital’s efforts to save patients’ lives and the university’s efforts to keep students safe.